GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Sep 2024 01:20 PM
RNS
Statement: Zantac (ranitidine) litigation
17 Sep 2024 07:00 AM
RNS
Japan Filing Acceptance: Blenrep Multiple Myeloma
13 Sep 2024 07:00 AM
RNS
China Breakthrough Therapy Designation for Blenrep
12 Sep 2024 03:30 PM
RNS
Director/PDMR Shareholding
12 Sep 2024 07:00 AM
RNS
Positive mRNA flu vaccine Phase II headline data
11 Sep 2024 05:27 PM
RNS
Statement: Zantac (ranitidine) litigation
11 Sep 2024 03:30 PM
RNS
Change of Registered Office
11 Sep 2024 07:00 AM
RNS
Update on phase I/II therapeutic HSV vaccine trial
09 Sep 2024 02:30 PM
RNS
Depemokimab late-breaking data presented at ERS
06 Sep 2024 03:30 PM
RNS
Director/PDMR Shareholding
06 Sep 2024 07:00 AM
RNS
Positive Phase III results for Nucala in COPD
02 Sep 2024 03:00 PM
RNS
Total Voting Rights
29 Aug 2024 07:00 AM
RNS
EMA approval on Arexvy for 50-59 at risk
28 Aug 2024 07:10 AM
RNS
SENKU Designation for Bepirovirsen in Japan
28 Aug 2024 07:05 AM
RNS
Nucala approved in Japan for use in CRSwNP
28 Aug 2024 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
21 Aug 2024 03:30 PM
RNS
Director/PDMR Shareholding
20 Aug 2024 03:30 PM
RNS
Director/PDMR Shareholding
20 Aug 2024 07:00 AM
RNS
B7-H3 ADC US FDA Breakthrough Therapy Designation
16 Aug 2024 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
12 Aug 2024 03:30 PM
RNS
Director/PDMR Shareholding
06 Aug 2024 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
02 Aug 2024 07:00 AM
RNS
FDA Expands Jemperli Approval
01 Aug 2024 03:00 PM
RNS
Total Voting Rights
31 Jul 2024 07:00 AM
RNS
2nd Quarter Results
29 Jul 2024 08:18 AM
RNS
Statement: Zantac (ranitidine) litigation
29 Jul 2024 07:00 AM
RNS
CHMP positive opinion on Arexvy for 50-59 at risk
19 Jul 2024 10:36 AM
RNS
Blenrep EMA Filing Acceptance
18 Jul 2024 03:30 PM
RNS
Director/PDMR Shareholding
16 Jul 2024 03:30 PM
RNS
Director/PDMR Shareholding
15 Jul 2024 03:30 PM
RNS
Director/PDMR Shareholding
12 Jul 2024 03:30 PM
RNS
Director/PDMR Shareholding
03 Jul 2024 07:00 AM
RNS
GSK and CureVac collaboration restructured
01 Jul 2024 03:00 PM
RNS
Total Voting Rights
28 Jun 2024 05:37 PM
RNS
Statement: Zantac (ranitidine) litigation
24 Jun 2024 07:05 AM
RNS
Omjjara approved in Japan for myelofibrosis
24 Jun 2024 07:00 AM
RNS
EMA validates Jemperli marketing authorisation
21 Jun 2024 03:30 PM
RNS
Director/PDMR Shareholding
12 Jun 2024 03:30 PM
RNS
Director/PDMR Shareholding
11 Jun 2024 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
10 Jun 2024 06:27 PM
RNS
Statement: Zantac (ranitidine) litigation
10 Jun 2024 07:00 AM
RNS
FDA approves Arexvy for adults 50-59 at risk
03 Jun 2024 03:00 PM
RNS
Total Voting Rights
03 Jun 2024 01:03 PM
RNS
Unprecedented results in Jemperli trial continue
03 Jun 2024 07:05 AM
RNS
ASCO positive Blenrep DREAMM-8 trial results
03 Jun 2024 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
24 May 2024 07:00 AM
RNS
Statement: Zantac (ranitidine) litigation
21 May 2024 07:00 AM
RNS
Positive phase III asthma results for depemokimab
20 May 2024 03:30 PM
RNS
Director/PDMR Shareholding
17 May 2024 07:00 AM
RNS
GSK completes sale of shares in Haleon plc

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings